Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides

Nucleic Acids Research

Volumn 34, Issue 6, 2006, Pages 1900-1911

  Duca, Maria ^a,b,c,d   Guianvarc'h, Dominique ^a,b,c,d   Oussedik, Kahina ^a,b,c,d   Halby, Ludovic ^a,b,c,d   Garbesi, Anna ^e   Dauzonne, Daniel ^f   Monneret, Claude ^f   Osheroff, Neil ^g   Giovannangeli, Carine ^a,b,c,d   Arimondo, Paola B ^a,b,c,d,h  

^a CNRS   (France)

^b MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

^c INSERM   (France)

^d Istituto di Sintesi Organica e Fotoreattivita del Consiglio Nazionale delle Ricerche ^*  (France)

^e CNR   (Italy)

^f INSTITUT CURIE   (France)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Centre National de la Recherche Scientifique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOUBLE STRANDED DNA; ETOPOSIDE DERIVATIVE; OLIGONUCLEOTIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; ETOPOSIDE; OLIGODEOXYRIBONUCLEOTIDE; TRIPLEX DNA;

ARTICLE; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DNA CLEAVAGE; DNA SEQUENCE; DNA STRAND BREAKAGE; DNA STRUCTURE; DRUG CONJUGATION; DRUG TARGETING; GENE TARGETING; GENOME ANALYSIS; LEUKEMIA; MOLECULAR BIOLOGY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; CHEMISTRY; DNA DAMAGE; DNA FOOTPRINTING; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DNA; DNA DAMAGE; DNA FOOTPRINTING; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; OLIGODEOXYRIBONUCLEOTIDES;

EID: 33645819360     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkl126     Document Type: Article

References (46)

1. Champoux,J.J. (2001) DNA topoisomerases: Structure, function, and mechanism. Annu. Rev. Biochem, 70, 369-413.
2. Wang,J.C. (2002) Cellular roles of DNA topoisomerases: A molecular perspective. Nature Rev. Mol. Cell. Biol, 3, 430-440.
3. Wang,J.C. (1996) DNA topoisomerases. Annu. Rev. Biochem, 65, 635-692.
4. Burden,D.A. and Osheroff,N. (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1400, 139-154.
5. Capranico,G. and Binaschi,M. (1998) DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim. Biophys. Acta, 1400, 185-194.
6. Capranico,G., Zagotto,G. and Palumbo,M. (2004) Development of DNA topoisomerase-related therapeutics: A short perspective of new challenges. Curr. Med. Chem. Anti-Canc. Agents, 4, 335-345.
7. Hande,K.R. (1998) Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer, 34, 1514-1521.
8. Hande,K.R. (2003) Topoisomerase II inhibitors. Cancer Chemother. Biol. Response Modif, 21, 103-125.
9. Baldwin,E.L. and Osheroff,N. (2005) Etoposide, topoisomerase II and cancer. Curr. Med. Chem. Anti-Canc. Agents, 5, 363-372.
10. Kaufmann,S.H. (1998) Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim. Biophys. Acta, 1400, 195-211.
11. Sordet,O., Khan,Q.A., Kohn,K.W. and Pommier,Y. (2003) Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anti-Canc. Agents, 3, 271-290.
12. Felix,C.A. (1998) Secondary leukemias induced by topoisomerase-targeted drugs. Biochim. Biophys. Acta, 1400, 233-255.
13. Lovett,B.D., Lo Nigro,L., Rappaport,E.F., Blair,I.A., Osheroff,N., Zheng,N., Megonigal,M.D., Williams,W.R., Nowell,P.C. and Felix,C.A. (2001) Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Proc. Natl Acad. Sci. USA, 98, 9802-9807.
14. Lovett,B.D., Strumberg,D., Blair,I.A., Pang,S., Burden,D.A., Megonigal,M.D., Rappaport,E.F., Rebbeck,T.R., Osheroff,N., Pommier,Y.G. et al. (2001) Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry, 40, 1159-1170.
15. Whitmarsh,R.J., Saginario,C., Zhuo,Y., Hilgenfeld,E., Rappaport,E.F., Megonigal,M.D., Carroll,M., Liu,M., Osheroff,N., Cheung,N.K. et al. (2003) Reciprocal DNA topoisomerase II cleavage events at 50′-TATTA-3′ sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing. Oncogene, 22, 8448-8459.
16. Matteucci,M., Lin,K.-Y., Huang,T., Wagner,R., Sternbach,D.D., Mehrotra,M. and Besterman,J.M. (1997) Sequence-specific targeting of duplex DNA using a camptothecin-triple helix forming oligonucleotide conjugate and topoisomerase I. J. Am. Chem. Soc, 119, 6939-6940.
17. Arimondo,P.B., Bailly,C., Boutorine,A., Sun,J.S., Garestier,T. and Hélène,C. (1999) Targeting topoisomerase I cleavage to specific sequences of DNA by triple helix-forming oligonucleotide conjugates. A comparison between a rebeccamycin derivative and camptothecin. C R Acad. Sci. III, 322, 785-790.
18. Arimondo,P.B., Boutorine,A., Baldeyrou,B., Bailly,C., Kuwahara,M., Hecht,S.M., Sun,J.S., Garestier,T. and Hélène,C. (2002) Design and optimization of camptothecin conjugates of triple helix-forming oligonucleotides for sequence-specific DNA cleavage by topoisomerase I. J. Biol. Chem, 277, 3132-3140.
19. Pommier,Y. (2004) Camptothecins and topoisomerase I: A foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: Importance of DNA replication, repair and cell cycle checkpoints. Curr. Med. Chem. Anti-Canc. Agents, 4, 429-434.
20. Arimondo,P., Bailly,C., Boutorine,A., Asseline,U., Sun,J.S., Garestier,T. and Hélène,C. (2000) Linkage of a triple helix-forming oligonucleotide to amsacrine-4-carboxamide derivatives modulates the sequence-selectivity of topoisomerase II-mediated DNA cleavage. Nucleosides Nucleotides Nucleic Acids, 19, 1205-1218.
21. Guianvarc'h,D., Duca,M., Boukarim,C., Kraus-Berthier,L., Leonce,S., Pierre,A., Pfeiffer,B., Renard,P., Arimondo,P.B., Monneret,C. et al. (2004) Synthesis and biological activity of sulfonamide derivatives of epipodophyllotoxin. J. Med. Chem, 47, 2365-2374.
22. Duca,M., Guianvarc'h,D., Meresse,P., Bertounesque,E., Dauzonne,D., Kraus-Berthier,L., Thirot,S., Leonce,S., Pierre,A., Pfeiffer,B. et al. (2005) Synthesis and biological study of a new series of 4′-demethylepipodophyllotoxin derivatives. J. Med. Chem, 48, 593-603.
23. Duca,M., Oussedik,K., Ceccaldi,A., Halby,L., Guianvarc'h,D., Dauzonne,D., Monneret,C., Sun,J.S. and Arimondo,P.B. (2005) Triple helix-forming oligonucleotides conjugated to new inhibitors of topoisomerase II: Synthesis and binding properties. Bioconjug Chem, 16, 873-884.
24. Bromberg,K.D., Burgin,A.B. and Osheroff,N. (2003) A two-drug model for etoposide action against human topoisomerase IIalpha. J. Biol. Chem, 278, 7406-7412.
25. Pinney,K.G. and Katzenellenbogen,J.A. (1991) Synthesis of a tetrafluoro-substituted aryl azide and its protio analogue as photoaffinity labeling reagents for the estrogen receptor. J. Org. Chem., 56, 3125-3133.
26. Cantor,C.R., Warshaw,M.M. and Shapiro,H. (1970) Oligonucleotides interactions III. Circular dichroism studies of the conformation of deoxyoligonucleotides. Biopolymers, 9, 1059-1077.
27. Grimm,G.N., Boutorine,A.S. and Hélène,C. (2000) Rapid routes of synthesis of oligonucleotide conjugates from non-protected oligonucleotides and ligands possessing different nucleophilic or electrophilic functional groups. Nucleosides Nucleotides Nucleic Acids, 19, 1943-1965.
28. Arimondo,P., Boukarim,C., Bailly,C., Dauzonne,D. and Monneret,C. (2000) Design of two etoposide-amsacrine conjugates: Topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des, 15, 413-421.
29. Froehler,B.C., Jones,R.J., Cao,X.D. and Terhorst,T.J. (1993) Oligonucleotides derived from 5-(1-propynyl)-2′-O- allyl-uridine and 5-(1-propynyl)-2′-O-allyl-cytidine: Synthesis and RNA duplex formation. Tetrahedron Lett., 34, 1003-1006.
30. Lacroix,L., Lacoste,J., Reddoch,J.F., Mergny,J.L., Levy,D.D., Seidman,M.M., Matteucci,M.D. and Glazer,P.M. (1999) Triplex formation by oligonucleotides containing 5-(1-propynyl)-2′-deoxyuridine: Decreased magnesium dependence and improved intracellular gene targeting. Biochemistry, 38, 1893-1901.
31. Arimondo,P.B., Moreau,P., Boutorine,A., Bailly,C., Prudhomme,M., Sun,J.S., Garestier,T. and Hélène,C. (2000) Recognition and cleavage of DNA by rebeccamycin- or benzopyridoquinoxaline conjugated of triple helix-forming oligonucleotides. Bioorg. Med. Chem, 8, 777-784.
32. Lee,M.P., Sander,M. and Hsieh,T. (1989) Nuclease protection by Drosophila DNA topoisomerase II. Enzyme/DNA contacts at the strong topoisomerase II cleavage sites. J. Biol. Chem, 264, 21779-21787.
33. Spitzner,J.R., Chung,I.K. and Muller,M.T. (1990) Eukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats. Nucleic Acids Res, 18, 1-11.
34. Thomsen,B., Bendixen,C., Lund,K., Andersen,A.H., Sorensen,B.S. and Westergaard,O. (1990) Characterization of the interaction between topoisomerase II and DNA by transcriptional footprinting. J. Mol. Biol, 215, 237-244.
35. Capranico,G., Guano,F., Moro,S., Zagotto,G., Sissi,C., Gatto,B., Zunino,F., Menta,E. and Palumbo,M.(1998) Mapping drug interactions at the covalent topoisomerase II-DNA complex by bisantrene/amsacrine congeners. J. Biol. Chem, 273, 12732-12739.
36. Freudenreich,C.H. and Kreuzer,K.N. (1994) Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. Proc. Natl Acad. Sci. USA, 91, 11007-11011.
37. Arimondo,P.B. and Hélène,C. (2001) Design of new anti-cancer agents based on topoisomerase poisons targeted to specific DNA sequences. Curr. Med. Chem. Anti-Canc. Agents, 1, 219-235.
38. Arimondo,P.B., Angenault,S., Halby,L., Boutorine,A., Schmidt,F., Monneret,C., Garestier,T., Sun,J.S., Bailly,C. and Hélène,C. (2003) Spatial organization of topoisomerase I-mediated DNA cleavage induced by camptothecin-oligonucleotide conjugates. Nucleic Acids Res, 31, 4031-4040.
39. Okada,Y., Ito,Y., Kikuchi,A., Nimura,Y., Yoshida,S. and Suzuki,M. (2000) Assignment of functional amino acids around the active site of human DNA topoisomerase IIalpha. J. Biol. Chem, 275, 24630-24638.
40. Strumberg,D., Nitiss,J.L., Dong,J., Kohn,K.W. and Pommier,Y. (1999) Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions. J. Biol. Chem, 274, 28246-28255.
41. Leroy,D., Kajava,A.V., Frei,C. and Gasser,S.M. (2001) Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA. Biochemistry, 40, 1624-1634.
42. Gruger,T., Nitiss,J.L., Maxwell,A., Zechiedrich,E.L., Heisig,P., Seeber,S., Pommier,Y. and Strumberg,D. (2004) A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II. Antimicrob. Agents Chemother., 48, 4495-4504.
43. Jiang,X. (2005) Random mutagenesis of the B′A′ core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide. Biochem. Biophys. Res. Commun, 327, 597-603.
44. Vilain,N., Tsai-Pflugfelder,M., Benoit,A., Gasser,S.M. and Leroy,D. (2003) Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha. Nucleic Acids Res, 31, 5714-5722.
45. Classen,S., Olland,S. and Berger,J.M. (2003) Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc. Natl Acad. Sci. USA, 100, 10629-10634.
46. Ishida,R., Iwai,M., Hara,A. and Andoh,T. (1996) The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule. Anticancer Res., 16, 2735-2740.